Vertex (VRTX) Is Buying Crinetics For $10 Billion And Entering Endocrinology

Summary

Vertex Pharmaceuticals is acquiring Crinetics Pharmaceuticals for $10 billion, marking Vertex's entry into the endocrinology market. The acquisition demonstrates Vertex's strategy to expand beyond its current therapeutic focus.